Managing Abnormal Breast and Cervical Cancer Screening Results in Viet Nam: Risk-Based Triage, Appropriate Evaluation and Follow-Up Accountability
DIAGNOSTIC PATHWAYS & RELIABILITYMEASUREMENT, LEARNING & IMPROVEMENT
11/5/202615 min read


Managing Abnormal Breast and Cervical Cancer Screening Results in Viet Nam: Risk-Based Triage, Appropriate Evaluation and Follow-Up Accountability
An abnormal cancer screening result can be frightening, even when cancer has not been diagnosed. A woman may be asked to return for additional breast imaging after a mammogram. Another may receive a positive human papillomavirus (HPV) test and worry that she has cervical cancer. Both need clear information about their results, but the appropriate next steps may be very different.
For healthcare providers, identifying an abnormality is only part of the process. A screening result may be accurately reported and communicated, yet the recommended evaluation may never take place. A referral might be issued without confirmation that the woman attended her appointment. Further investigations may occur at another healthcare facility without the original screening provider receiving information about the outcome.
These gaps can reduce the potential benefits of screening, even when the initial examination was performed correctly.
In February 2026, Viet Nam's Ministry of Health issued the National Action Plan for Breast and Cervical Cancer Prevention and Control, 2026–2035. The plan emphasizes early detection, timely diagnosis, appropriate management, coordinated services, and stronger information systems to support continuity of care.
International guidance has also evolved. In May 2026, the World Health Organization (WHO) published recommendations on HPV DNA genotyping for cervical cancer prevention. This was followed in July by guidance on implementing HPV-based cervical cancer screening programs, including strategies to help women with positive results remain engaged in the subsequent care process.
These developments highlight an important question for healthcare organizations: when an abnormal screening result is identified, can the system establish whether the woman received the evaluation or management appropriate to her clinical risk?
Understanding What an Abnormal Screening Result Means
Screening is generally intended to identify possible disease or increased risk before symptoms appear. It may reveal a finding that requires further assessment, but the screening result itself does not always establish a diagnosis.
In breast screening, an abnormal mammogram may reflect a benign change, an area requiring additional imaging, or a suspicious lesion that warrants tissue sampling. An incomplete imaging assessment is different from a suspicious finding because the available information may not yet support a final conclusion.
Cervical cancer screening has a different biological basis. A positive high-risk HPV test indicates that a type of HPV associated with cervical precancer and cancer risk has been detected. It does not establish that a woman has precancer or invasive cervical cancer. Many HPV infections clear or become undetectable without progressing to clinically significant disease, although persistent infection with carcinogenic HPV types can increase the risk of cervical abnormalities.
These distinctions affect what should happen next. Some women require diagnostic investigations, while others may benefit from additional triage testing, surveillance, or preventive treatment under an appropriate clinical pathway.
Screening must also be distinguished from investigating symptoms. A woman presenting with a palpable breast mass, concerning nipple changes, unexplained abnormal vaginal bleeding, or other potentially significant symptoms may need diagnostic assessment regardless of her screening history. A reassuring screening result should not automatically override a clinically concerning presentation.
The first task is therefore to understand what the result actually indicates, what remains uncertain, and which subsequent action is appropriate.
Breast Screening: Reaching an Appropriate Diagnostic Assessment
Breast cancer screening commonly relies on imaging, with further evaluation guided by the characteristics of the finding, previous examinations, and relevant clinical information.
The American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS) provides a standardized approach to describing breast imaging findings, assigning assessment categories, and communicating management recommendations.
The ACR BI-RADS v2025 Manual, released in December 2025, supports consistent reporting, professional communication, and outcome monitoring across breast imaging modalities.
Viet Nam's Ministry of Health also issued the professional guideline on breast cancer screening and early detection under Decision No. 3898/QD-BYT, dated December 18, 2025, which took effect on February 12, 2026.
These frameworks help distinguish findings requiring additional imaging from those for which surveillance or tissue diagnosis may be appropriate.
For example, a BI-RADS 0 assessment indicates that the imaging evaluation is incomplete. Additional imaging or comparison with previous examinations may be required before a final assessment can be established. The classification does not mean that cancer has been identified, but the initial evaluation remains unfinished.
A BI-RADS 3 assessment, assigned after an appropriate diagnostic evaluation, indicates a probably benign finding for which short-interval imaging follow-up may be recommended. More suspicious findings, such as those classified as BI-RADS 4 or 5, generally warrant tissue diagnosis.
These categories should not be treated as interchangeable. Their interpretation and subsequent management require appropriate professional assessment.
Previous breast images may also influence clinical decisions. A finding that appears concerning on one examination may be interpreted differently when earlier studies demonstrate long-term stability. Conversely, a developing abnormality may require further investigation even when previous findings were considered benign.
When biopsy is performed, the diagnostic process should include appropriate assessment of imaging-pathology concordance. A benign pathology result does not necessarily resolve a suspicious imaging abnormality if the tissue findings do not adequately explain the original concern. Further professional review or additional sampling may be needed.
The appropriate endpoint is therefore not simply completion of another mammogram or biopsy. It is a clinically justified assessment of the original finding, which may establish benign disease, identify malignancy, support a surveillance plan, or indicate that further evaluation remains necessary.
For breast screening services, this distinction is particularly important. A higher rate of additional imaging or biopsy does not automatically indicate better diagnostic quality. The objective is to ensure that women receive investigations appropriate to their findings without avoidable delay or unnecessary procedures.
Cervical Screening: Managing HPV-Positive Results According to Clinical Risk
Cervical cancer screening follows a different pathway because persistent infection with carcinogenic HPV types is the principal cause of cervical cancer.
HPV-based screening can identify women at increased risk of developing cervical precancer, often before visible abnormalities or symptoms appear. However, the clinical significance of a positive result depends on more than the presence of HPV alone.
The HPV type detected, previous screening history, additional triage findings, immune status, and other relevant clinical circumstances may influence the recommended management.
WHO's guideline published on May 8, 2026, examines the use of HPV DNA genotyping to improve risk stratification within cervical cancer screening programs. It considers testing approaches that identify HPV positivity without genotype-specific information, those providing limited genotyping, and those offering more extended genotype classification.
The additional information may help determine which women need more immediate evaluation and which may be managed through other evidence-informed pathways.
However, more detailed genotype information does not automatically make a screening program safer. Its value depends partly on whether the healthcare system can provide the additional assessment, surveillance, or treatment that the results indicate.
The 2026 WHO guidance considers differences in program capacity, available resources, workforce competence, follow-up arrangements, and treatment services. Recommendations must therefore be interpreted within the relevant clinical and implementation context.
Depending on the applicable screening algorithm and individual circumstances, a positive HPV result may lead to further triage testing, repeat testing at an appropriate interval, colposcopic assessment, or treatment through an established cervical precancer prevention pathway.
Certain evidence-based screening and treatment strategies allow treatment without prior histological confirmation in appropriately selected circumstances. These approaches require suitable eligibility assessment, qualified professionals, appropriate facilities, and safeguards for women whose findings suggest invasive cancer. They should not be interpreted as a universal recommendation to treat every HPV-positive woman or as automatically authorized for every healthcare setting in Viet Nam.
When invasive disease is suspected, appropriate diagnostic evaluation is necessary rather than routine management as uncomplicated screen-detected precancer.
WHO's July 2026 implementation guidance also emphasizes the importance of retaining women who screen positive throughout subsequent care. Screening effectiveness depends not only on access to testing but also on reliable communication, appropriate clinical decisions, and the ability to complete the recommended pathway.
This is especially relevant when HPV self-sampling is introduced. Self-sampling may improve access where appropriately implemented, but it does not remove the need for reliable specimen identification, validated testing, result communication, and access to appropriate follow-up services.
An HPV-positive result should therefore lead to a risk-based management decision within the applicable screening program, rather than automatically triggering the same procedure for every woman.
What Viet Nam's National Action Plan Means for Follow-Up
Viet Nam's National Action Plan for Breast and Cervical Cancer Prevention and Control, issued under Decision No. 358/QD-BYT on February 3, 2026, provides an important framework for strengthening prevention, screening, diagnosis, treatment, and continuity of care.
For breast cancer, the plan sets a target that 50% of women with suspicious signs or abnormal screening results receive a definitive diagnosis within 60 days of the first clinical visit by 2030. This target increases to 80% by 2035.
The wording of this indicator matters. It includes women presenting with suspicious clinical signs as well as those with abnormal screening results. The measurement period begins from the first clinical visit specified in the plan, which is not necessarily the date an abnormal screening report becomes available.
The indicator is a national program target for breast cancer. It is not a universal legal or clinical deadline for every abnormal mammogram and should not be applied automatically to HPV-positive results or other cancer screening findings.
Some suspicious findings may warrant faster investigation, while others may appropriately be managed through surveillance or additional testing at an interval determined by the relevant clinical pathway.
The plan also establishes a separate target for cervical cancer. It aims for appropriate detection and management, according to professional guidance, of 80% of women with cervical precancerous lesions or invasive cervical cancer by 2030, increasing to 90% by 2035.
These targets reflect the differences between the two conditions. Timely diagnostic assessment is an important performance concern in breast cancer, while cervical cancer prevention also depends heavily on the identification and appropriate management of precancerous disease.
The national plan further emphasizes stronger referral arrangements, professional capacity, access to services, and information systems capable of supporting continuity across screening, diagnosis, treatment, and follow-up.
These objectives are relevant to healthcare organizations across Viet Nam, but they should not be interpreted as evidence that all proposed arrangements have already been implemented uniformly.
Facilities may differ in staffing, diagnostic capacity, information technology, referral relationships, and access to specialist services. Translating the national priorities into practice requires an understanding of each organization's authorized activities and available resources.
When Follow-Up Crosses Healthcare Facilities
An abnormal screening result may be identified at one healthcare facility and require further evaluation at another.
A woman might undergo breast screening at an outpatient clinic, receive diagnostic imaging at a hospital, and require biopsy or specialist assessment elsewhere. In cervical screening, sample collection, laboratory testing, triage, colposcopy, and subsequent management may also involve different providers.
These arrangements can improve access to specialized care, but they create opportunities for important information to become disconnected.
Consider a woman referred for additional imaging after an abnormal screening mammogram. The screening service issues a referral, but she has difficulty obtaining an appointment. Several weeks pass, and the original provider receives no information about whether the evaluation occurred.
The referral may appear complete in the administrative record, even though the original clinical concern remains unresolved.
This does not necessarily mean that the initial imaging assessment was incorrect. The weakness may lie in how information and responsibility move between services.
Issuing a referral, confirming that it was received, verifying that the woman attended, and establishing the clinical outcome are different steps. A reliable follow-up process should distinguish them rather than treating a referral document as evidence that the recommended evaluation occurred.
Responsibilities must also be understood within the professional and legal roles of the participating organizations.
A screening provider should have an appropriate process for identifying findings requiring action and communicating relevant information. The receiving clinician or service is responsible for making clinical decisions within its authorized scope. Where ongoing coordination is necessary, the participating organizations should establish how outstanding actions are managed.
Not every screening provider is responsible for monitoring every aspect of subsequent care indefinitely. The extent of its responsibility depends on the services provided, applicable legal and professional requirements, and arrangements for referral or transfer of care.
Nevertheless, a clinically important finding should not be left without an identifiable next step simply because the woman has been referred elsewhere.
A screening coordinator, designated clinical team, or case-management function may help maintain communication and identify unresolved cases. Such arrangements can support continuity without replacing the professional judgment or responsibilities of those providing clinical care.
Communicating Results With Clarity and Sensitivity
An abnormal cancer screening result can create considerable anxiety, particularly when the patient does not understand what it means.
For some women, being asked to return after a mammogram may feel almost equivalent to receiving a cancer diagnosis. Others may assume that a positive HPV test means they have cervical cancer.
These interpretations can lead to unnecessary distress. Excessive reassurance can also be harmful if it causes clinically important follow-up to be delayed.
Communication should explain what the test has identified, what remains uncertain, and why a particular next step is recommended.
For breast screening, women should understand whether additional imaging is needed to complete the assessment, whether surveillance has been advised, or whether a finding requires further diagnostic investigation.
For HPV-positive results, clinicians should explain that HPV infection and cervical cancer are different conditions. A positive test does not establish when the infection was acquired or the circumstances of transmission. This distinction matters because HPV-related findings may raise concerns about relationships, stigma, and confidentiality.
Patients should also receive understandable information about where further assessment can be obtained, the recommended timeframe, and whom to contact if difficulties arise.
Practical barriers deserve attention. Travel costs, work commitments, family responsibilities, appointment availability, and difficulties navigating referral systems may affect whether women receive the recommended care.
These challenges can be particularly significant when screening and diagnostic services are provided at different locations.
Respectful communication can help identify barriers and support informed decisions. However, patient participation should not become a substitute for appropriate organizational responsibility.
Simply telling a woman to seek further evaluation does not necessarily establish that all relevant clinical and organizational responsibilities have been fulfilled.
Measuring Follow-Up Quality Without Misclassifying Outcomes
Screening coverage is an important public health indicator, but it does not show whether women with abnormal results receive appropriate subsequent care.
A screening program may reach more women while continuing to experience delays in diagnostic evaluation or gaps in follow-up.
Healthcare organizations therefore need measures that reflect what happens after a result requiring further action becomes available.
In breast screening, useful indicators may include the proportion of women requiring additional diagnostic imaging who complete that assessment, the proportion of suspicious findings receiving appropriate tissue evaluation, and the time taken to reach a documented clinical disposition.
In cervical screening, relevant indicators may examine whether HPV-positive women receive the triage, surveillance, colposcopy, or treatment appropriate to their results and the applicable algorithm.
These measures require clearly defined patient groups, starting points, and clinical endpoints.
A woman whose breast imaging findings require biopsy should not be classified as having completed the diagnostic pathway simply because additional imaging was performed. Conversely, a woman whose finding is appropriately assessed as probably benign should not be considered inadequately managed merely because biopsy was not performed.
Similarly, an HPV-positive woman assigned to evidence-based surveillance should not automatically be classified as lost to follow-up before the recommended surveillance interval has elapsed. However, a future appointment being scheduled should not be counted as an examination already completed.
An appropriate clinical plan, a planned action that remains outstanding, and an action that has been completed are different states.
Care received outside the original screening facility creates another measurement challenge. If women who attend other hospitals are excluded from follow-up statistics, the results may underestimate appropriate care. If women who cannot be contacted are removed from the denominator, reported completion rates may appear misleadingly high.
Informed refusal, documented transfer of responsibility, missed appointments, unsuccessful contact attempts, and clinically completed evaluation should be distinguished rather than grouped together as completed cases.
The purpose of these measures is not simply to produce a high completion rate. It is to identify where important actions may be delayed, overlooked, or incorrectly recorded as completed.
Measurement should also consider the appropriateness of investigations. More biopsies, more referrals, or shorter intervals between examinations do not necessarily represent better outcomes if they lead to unnecessary procedures without improving clinically meaningful care.
For healthcare organizations, some of the most valuable information comes from examining cases that did not progress as expected, especially when a clinically significant finding remained unresolved.
Strengthening Follow-Up Within Viet Nam's Legal Framework
International recommendations can support the design of reliable screening programs, but their status must be distinguished from Vietnamese law.
WHO guidance and the ACR BI-RADS framework provide important professional references. Their application should be considered alongside relevant Ministry of Health guidance, the authorized scope of healthcare services, professional qualifications, clinical circumstances, and available resources.
They should not automatically be presented as independent legal requirements for every healthcare organization in Viet Nam.
The Law on Medical Examination and Treatment No. 15/2023/QH15, as amended, provides a broader legal framework for healthcare practice and the responsibilities of healthcare facilities.
Article 60 addresses healthcare facility responsibilities, including referral or transfer to appropriate facilities in circumstances specified by law. Article 69 establishes requirements concerning medical records, including their creation, maintenance, confidentiality, and access.
These provisions are relevant to clinical documentation and continuity of care where applicable. However, they should not be interpreted as independently requiring every screening provider to operate the same follow-up registry or administrative tracking system.
Healthcare organizations may establish additional quality improvement procedures to strengthen reliability, provided these are consistent with applicable law and professional requirements.
The protection of personal health information is another important consideration.
Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.
Screening and follow-up systems may contain identifiable health information, imaging findings, HPV test results, referral records, and patient contact details. Organizations should assess the lawful basis for collecting, processing, retaining, and sharing such information and apply relevant requirements concerning confidentiality, access controls, information security, and data transfers.
Applicable consent requirements, legal exceptions, and conditions for information sharing depend on the nature and purpose of the processing activity.
A follow-up registry intended to support safer care should collect and use information for clearly defined purposes while protecting patients against unauthorized access or disclosure.
Clinical continuity and patient privacy should be addressed together rather than treated as competing priorities.
Making Follow-Up More Reliable in Everyday Practice
Improving the management of abnormal screening results does not necessarily require a sophisticated national information platform or a large technology project.
A healthcare organization can begin by reviewing a defined group of screening results that require additional action.
For breast screening, this might involve women recalled for diagnostic imaging or those with suspicious findings requiring biopsy. For cervical screening, it could involve HPV-positive results requiring further triage, surveillance, specialist assessment, or treatment.
The review should establish whether results were appropriately classified, whether recommendations were clearly documented and communicated, and whether the organization can determine what happened afterward.
It may reveal practical problems that are relatively straightforward to address. Reports may contain unclear recommendations. Appointment arrangements may be difficult for patients to navigate. Referral feedback may be inconsistent, or the organization may lack an accessible record of cases requiring further action.
Different problems call for different solutions.
Clearer reporting may improve communication between screening and diagnostic services. Defined coordination responsibilities may reduce uncertainty about referrals. A securely managed worklist may help teams recognize clinically important cases that have not progressed as expected.
Where services are provided by separate organizations, practical communication arrangements and appropriate information-sharing procedures may be more useful than introducing additional internal reporting requirements.
Clinical teams, imaging and laboratory professionals, appointment coordinators, and quality personnel should contribute to designing these arrangements so that responsibilities are realistic and fit the actual workflow.
After changes are introduced, organizations can examine whether unresolved findings and avoidable delays have decreased without creating unnecessary testing, administrative workload, or additional barriers to care.
The objective is not to standardize every woman's clinical management. It is to make the processes supporting appropriate individualized decisions more dependable.
From Abnormal Screening Results to Safer Diagnostic Care
Breast and cervical cancer screening can help identify important health concerns before symptoms develop, but an abnormal result is only the beginning of a clinical decision.
For one woman, additional breast imaging may establish that a finding is benign. Another may require biopsy and further diagnostic evaluation. A positive HPV result may lead to surveillance, additional triage, colposcopy, or preventive treatment, depending on the clinical risk and the applicable screening pathway.
These outcomes differ, and a reliable healthcare system must recognize those differences.
Viet Nam's 2026–2035 national action plan, updated Ministry of Health guidance, and WHO's 2026 recommendations provide a timely opportunity to strengthen how screening results are translated into appropriate care.
The most meaningful improvements may begin with simple questions. Was the result correctly interpreted? Did the woman understand what it meant? Was the next step appropriate to her risk? And, where further action was needed, can the healthcare organization establish what happened?
The quality of a cancer screening program is not demonstrated only by how many women are screened. It also depends on whether women with abnormal results receive appropriate evaluation and follow-up, without avoidable delay or unnecessary intervention, and whether the healthcare system can account for what happens after the result is reported.
Selected References and Regulatory Sources
Ministry of Health of Viet Nam. Decision No. 358/QD-BYT, Promulgating the National Action Plan for Breast and Cervical Cancer Prevention and Control, 2026–2035. February 3, 2026.
Ministry of Health of Viet Nam. Decision No. 3898/QD-BYT, Promulgating the Professional Guideline on Breast Cancer Screening and Early Detection. December 18, 2025. Effective February 12, 2026.
World Health Organization. WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention: Use of Human Papillomavirus (HPV) DNA Genotyping. May 8, 2026.
World Health Organization. Evidence-Informed Guidance for the Implementation of HPV-Based Cervical Cancer Screening Programmes. July 14, 2026.
World Health Organization. WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention. Second edition. 2021.
World Health Organization. Global Breast Cancer Initiative Implementation Framework: Assessing, Strengthening and Scaling Up Services for the Early Detection and Management of Breast Cancer. 2023.
American College of Radiology. ACR BI-RADS v2025 Manual. Reston, VA: American College of Radiology; 2025.
National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, as amended. See also Consolidated Document No. 26/VBHN-VPQH, dated February 26, 2026.
National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.
Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Implementation Measures of the Law on Personal Data Protection. Effective January 1, 2026.
Professional Scope and Disclaimer
This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety, and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement, and quality improvement.
The content is intended for general professional education and discussion. It does not constitute individualized medical advice, clinical diagnosis, interpretation of a specific screening result, a recommendation for patient-specific investigations or treatment, a determination of professional error, or legal advice. References to international guidance and suggested quality improvement practices do not imply that they are automatically legally binding in Viet Nam.
Patient-specific decisions concerning screening, risk assessment, diagnostic evaluation, referral, surveillance, treatment, and follow-up must be made by appropriately qualified and authorized healthcare professionals in accordance with applicable Vietnamese law, relevant professional guidance, and individual clinical circumstances.
Diagnostic Excellence Vietnam does not provide clinical diagnosis or treatment services.
